泰诺麦博科创板IPO披露首轮问询回复

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. is seeking to raise 1.5 billion yuan through its IPO on the Sci-Tech Innovation Board, focusing on innovative biopharmaceuticals for blood product alternatives [1] Company Overview - Tainuo Maibo was established in 2015 and is dedicated to developing innovative biopharmaceuticals aimed at global markets [1] - The company’s core product is Staitoutamab, which is under scrutiny for its competitive advantages and commercialization potential [1] IPO Details - The IPO aims to raise funds for three projects, including new drug research and development [1] - The Shanghai Stock Exchange has raised questions regarding the company's technology advancement, sources of technology, and the specifics of the fundraising projects [1]